The file's text, extracted by GovTribe without its formatting.
STATEMENT OF WORK (SOW) for Reference Laboratory Services Boise VAMC Laboratory
1. SCOPE
a. The Reference Laboratory shall provide in accordance with all applicable federal, state, and local regulations, laws, and ordinances, and in accordance with the specifications outlined for accreditation certification if applicable, patient specimen testing for the specific range of referral testing within their capability.
b. Services shall include the performance of analytical testing as defined by the Laboratory's reference test manual, the reporting of analytical test results and consultative services as required assimilating the full scope of its laboratory operations to Boise VA Laboratory Services.
c. All requirements and provisions defined in the specifications of this solicitation will apply to any laboratory, i.e. branch, division, sub-contractor, etc. performing reference testing on behalf of the Reference Laboratory.
d. The VA Facilities will be responsible for specimen collection and will provide laboratory specimens prepared according to the Reference Laboratory's laboratory user’s manual, identified, and labeled for testing.
e. Period of performance starts 03/01/2026
2. SPECIFIC TASKS
a. Clinical Chemistry:
i. Reference Laboratory shall provide laboratory services to include: preanalytic processing as defined in Reference Laboratory published user’s manual; analysis, reporting of analytic results and interpretation of analytic clinical results. The number of tests requested under this contract will change throughout the life of the contract. The volumes or amounts shown in the solicitation are estimates only and impose no obligation on the VA.
ii. The Reference Laboratory shall also provide the following support services: supplies, customer service, courier service (to include pickup of specimens and transport of specimens to its laboratory), reporting services, and verification of certification. See Section 12.
iii. Provide all necessary supplies as defined in the laboratory user manual, to include, but not limited to the following:
1) Requisition forms or agreed computer ordering system
2) Specimen containers
3) Dry ice and appropriate container
4) Special instructions
5) Log books for samples sent out and results returned
6) Specimen carriers
7) All forms, including Chain of Custody forms
8) Special media or tubes for viral samples
9) All supplies for special tests (e.g., but not limited to, viral studies), including 24-hour urine containers with preservatives.
iv. The Reference Laboratory shall provide to the VA Facilities the supplies and equipment within one (1) week of receipt of the delivery order. The VA Facilities will request replenishment of supplies from the Reference Laboratory on an as needed basis via telephone or fax. A confirmation of the order shall be supplied to the VA within 24 hours.
v. All supplies shall be shipped FOB Destination.
b. Microbiology:
i. If required, the Reference Laboratory shall provide microbiology services for Boise VA Medical Center. The number of tests requested under this contract will change throughout the life of the contract.
ii. Contractor shall provide laboratory services for Microbiology to include pickup and transport of specimens from the Boise VA to its laboratory; pre-analytic processing as defined in its laboratory user’s manual; analysis, reporting of analytic results, and consultation regarding selection, collection, transportation and result interpretation. The contractor shall provide the following supplies/materials:
1) Special instructions
2) Specimen carriers
3) Special media or tubes for viral samples
4) All supplies for specimen preservation, special tests (e.g., but not limited to, viral studies)
iii. Microbiology preliminary reports shall be provided within 24hrs
3. Electronic Interface
a. If awarded the Reference Laboratory agrees to a transition period for providing a fully functioning interconnection for exchanging data between VISTA, VA Computer system, and the Reference Laboratory's electronic lab information system. During this time the Reference Laboratory will supply the VA Facility with available test menu and agrees to receive test orders as they are transitioned until full menu implementation.
b. System drivers must be compatible with the VA’s Vista Laboratory Electronic Data Exchange (LEDI) software. The server and interface software will be owned and maintained by the Reference Laboratory. The Reference Laboratory must have a signed MOU (Memorandum of Understanding) with the VA Network and Security Operations Center (NSOC) to utilize the One- VA VPN Tunnel.
c. This interconnection shall be protected through the use of VA approved encryption algorithms and products as required and in compliance with HIPPA guidelines. Connections at each end shall be located within a controlled access facility. All access shall be controlled by authentication methods to validate approved users.
d. Agrees to provide one full-time support person for new interface if new vendor.
4. TESTING METHODOLOGY, REFERENCE AND TURN AROUND TIME
a. Routine test results shall be reported within the specified turnaround time (TAT) which is defined from time of specimen pickup to when results are available. TAT is established by the VA facility. In general, majority of Clinical Chemistry should be completed within 1-5 days, see attachment for details. In general, majority of Microbiology should be completed within 2-5 days, see attachment for details. If testing is not within TAT, notify the VA Facilities of the new estimated TAT within 12 hours.
b. Testing methodology and reference ranges for a test must be defined in the Reference Laboratory user manual and/or website. Reference Laboratory shall advise facility of any changes in methodology, procedure, reference ranges and any new tests introduced 30 days in advance.
c. Reference Laboratory agrees to maintain the minimum acceptable service, reporting systems and quality control. Exception handling: Reference Laboratory will notify VA Facilities Laboratory Service within 12 hours of any problems with specimens received.
d. The VA Facilities will provide laboratory specimens prepared according to the Reference Laboratory's user’s manual, identified, and labeled for testing.
e. Routine Microbiology test results shall be reported, preliminary at minimum, within 24 hours (within agreed TAT per each test). STAT test results shall be reported within 2 hours or less of specimen pick-up. Critical Value test results shall be reported immediately. Stat test results will be faxed or telephoned to Laboratory Service. Telephoned results will be confirmed with a follow-up by vendor via fax.
f. The Reference Laboratory will have the ability to provide STAT testing results (24-hour TAT) at a local laboratory, as needed.
5. CUSTOMER SERVICE
a. The Reference Laboratory will provide VA Laboratory with a means of communication to permit immediate inquiry regarding the status of pending tests or specimen problem, 24 hours per day, 7 days per week.
b. The Reference Laboratory shall provide names and telephone numbers of technical Directors and Pathologists available to provide information.
c. The Reference Laboratory will be required to provide on-site (BVAMC) training of Boise personnel for processing laboratory send out specimens if a new vendor is selected. This training shall be funded by the awarded Reference Laboratory at no expense to the Boise VAMC.
6. COURIER SERVICES
a. The Reference Laboratory shall be responsible for transporting and storing specimens in such a manner as to ensure stability and integrity of the specimen where applicable. Reference Laboratory shall supply any special preservatives required for specimen preservation.
b. Transport samples in such a manner as to ensure the integrity of the specimen.
c. Reference Laboratory shall supply any special preservatives required for specimen preservation.
d. Reference Laboratory shall notify VA Facilities of any specimen problems or discrepancies from the submitted manifest within 24 hours after shipping.
e. The Reference Laboratory shall provide routine scheduled specimen pickup at a time mutually agreed upon by the VA facilities but not less than once a day.
f. The VA Facilities laboratory manager or designee shall notify the Reference Laboratory during weekends and federal holidays, via telephone, when a pick-up courier is required.
g. The Reference Laboratory shall provide STAT (reportable within two hours or less of specimen pickup) specimen capability.
7. DELIVERY AND REPORTING
a. Billing summaries shall begin the first day of the month and include the last day of the month.
b. Tests referred to another laboratory shall be at no additional transfer charge or confirmation charge to the government.
c. Deliveries must be accompanied by a delivery ticker or sales slip that contains the following information as a minimum:
1) Vendor Name
2) Applicable contract number
3) BPA, IDIQ Number, Task order number, and Purchase Order number
4) Date of Purchase
5) Date of Shipment
6) Description of item
7) Quantity of each item
8) Unit price and extended (quantity x unit price) price for each item
d. The Reference Laboratory shall provide a quarterly and end of year report showing sample issues, facility usage, and cost savings generated during the reporting period. The report will be due 45 days after the close of each government fiscal quarter.
e. Yearly antibiogram report to be supplied.
8. PERFORMANCE MONITORING
a. At the time of contract award the Contracting Officer will appoint a Contracting Officer Representative (COR) to assist with the contract monitoring requirements. The COR or designee will monitor such items as quality of service, contractor's ability to meet TAT's, correct billing, customer service, and review of the contractor's proficiency program.
b. Contractor shall provide to the COR or designee no later than Ninety (90) days prior to the end of each contract period a proficiency report. The COR or designee shall review the proficiency results. The contractor shall maintain a minimum of 95% success rate for proficiency testing to be considered successful. Failure to achieve 95% success rate two periods in a row could be grounds for Termination for Cause.
c. The COR or designee will ensure that services performed are in accordance with all terms and conditions of the contract.
d. The delegated COR or designee will notify the Contracting Officer of any non-compliance immediately upon his/her gaining knowledge of any such situation or incident. After such communication, the COR or designee will provide a written statement to the contracting officer along with any supporting documentation regarding the performance failure noted.
e. Upon receipt of a proper invoice, the COR or designee shall certify that the services identified have been performed. Once certification has been made, the invoice will be forward through the proper billing channels and payment shall be made to the Contractor.
f. It is the intention of both parties to conduct joint reviews prior to the expiration date of the contract to determine and evaluate if services being provided are in accordance with the contract terms, payments and billings are being properly handled and to jointly determine if this agreement is satisfactory to both parties in terms of services provided and consideration being received. This review may include. but not be limited to: analyzing all billings, payments, costs, administrative issues, patient satisfaction, quality of care and other related documentation that identities that services have been received.
g. Upon conclusion of the initial contract period, and in coordination with the Contracting Officer, the using service shall provide a statement to the Contracting Officer providing a summary of contractor actions and a statement that all requirements of the contract were fulfilled as agreed. This information shall be forwarded by the COR or designee to the Contracting Officer prior to exercising any extension of this agreement (at least 60 days prior to contract expiration).
9. LICENSING AND ACCREDITATION
a. Reference Laboratory shall provide copies of all licenses, permits, accreditation and certificates required by law. Laboratory Director shall be a licensed American Board of Pathology certified pathologist or appropriately certified bio-analyst.
b. All medical facilities providing laboratory services under the contract must possess a valid state license and meet JC standards as well as CLIA requirements and standards of the College of American Pathologists (CAP).
10. PERSONNEL
a. The Reference Laboratory shall make sure employees have current and valid professional certifications before starting work under this contract.
b. The Reference Laboratory staff shall meet personnel qualifications required by Clinical Laboratory Improvement Act (CLIA) '88 Guidelines.
c. The Government’s reserves the right to request information or certification from the contractor verifying they comply with this contract requirement. If discovered the contractor is not in compliance with this requirement the contract shall be terminated for cause in accordance with clause 52.212-4.
11. HOURS OF OPERATION
a. The Boise VA is open 24 hours a day, 7 days a week, 12 months of the year and may require services during those times.
12. PATIENT INFORMATION SAFETY
a. The Reference Laboratory shall not use or disclose Protected Health Information (PHI) other than as permitted or required by the agreement or as required by law.
b. The Reference Laboratory shall use appropriate safeguards to prevent use or disclosure of the PHI other than is provided for by this agreement.
c. The Reference Laboratory shall report immediately any breach of safeguards and mitigate any harmful effects related to the use or disclosure of PHI by the Reference Laboratory or any of its agents, including sub-contractors.
13. SECURITY REQUIREMENTS
The Reference Laboratory shall be responsible for adhering to the following statements as they relate to the contract. Boise VA in coordination with their site Information Security Officer (ISO) shall monitor the work performed by contractor personnel, including sub-contractors, on a periodic basis to make sure contractor personnel are following the stated security requirements.
14. Quality Assurance Surveillance Program
SOW
Task#
| Quality Monitor |
| Format |
| Calendar Days After CO Start |
| Acceptability Level |
| 1 |
| Licensures/Certificates |
| Copies |
| At initial award, and when renewed |
| 100% Received |
| 2 |
| Monthly Test Summary |
| One electronic copy |
| Monthly on the 10th work day |
| 100% Received |
| 3 |
| Contact Phone List |
| One electronic copy |
| At initial award, and when changes occur |
| 100% Received |
| 4 |
| Laboratory User Manual |
| Electronic copy and one hard copy |
| At initial award |
| 100% Received |
| 5 |
| Turn Around Time |
| One electronic copy |
| Monthly |
| 95% meets established limits |
| 6 |
| Proficiency Testing |
| One electronic copy |
| 90 days prior to the end of contract period |
| 95% meets success rates |
| 7 |
| Antibiogram Report |
| One electronic copy |
| Annually |
| 100% Received |
Table A: VA Turn Around Times for most common orders but not inclusive of all orders
| Test Ordered Name |
| TAT in days |
| Test Ordered Name |
| TAT in days |
| 5-HIAA,QUANT.,24 HR |
| 6 days |
| HEMOCHROMATOSIS |
| 5 days |
| ACHR BINDING ABS |
| 2 days |
| HLA B 27 DISEASE |
| 4 days |
| ALDOSTERONE/RENIN RA |
| 6 days |
| IGF-1 |
| 7 days |
| ALK PHOS ISOENZYME |
| 4 days |
| IGG, SUBCLASSES(1-4) |
| 3 days |
| ALLERGEN PROFILE FOOD |
| 3 days |
| IMMUNOGLOBULIN E |
| 4 days |
| ALLERGENS PANEL |
| 3 days |
| INFLIXIMAB (IFX) |
| 6 days |
| AMPHETAMINE (GC/MS) |
| 3 days |
| JC VIRUS DNA,PCR |
| 3 days |
| ANCA PANEL |
| 2 days |
| LAMOTRIGINE |
| 4 days |
| ANGIOTENSIN-CONVERTING |
| 2 days |
| LEAD, BLOOD |
| 2 days |
| ANTICARDIOLIP AB, IG |
| 3 days |
| LEVETIRACETAM |
| 4 days |
| ANTINUCLEAR AB |
| 4 days |
| LITHIUM |
| 3 days |
| BENZODIAZEPINES CONF |
| 3 days |
| LUPUS ANTICOAGULANT |
| 4 days |
| BETA-HYDROXYBUTYRATE |
| 2 days |
| LYME, TOTAL AB |
| 3 days |
| BK QUANT PCR |
| 2 days |
| MANGANESE, PLASMA |
| 5 days |
| CA 19-9 |
| 2 days |
| MEASLES/MUMPS/RUBELL |
| 4 days |
| CALCIUM, 24HR URINE |
| 2 days |
| METHADONE CONFIRM |
| 3 days |
| CALCIUM, IONIZED |
| 4 days |
| METHYLMALONIC ACID |
| 5 days |
| CALCULI, URINARY |
| 3 days |
| MYCOPHENOLIC ACID |
| 3 days |
| CANNABINOID (GC/MS) |
| 5 days |
| NON-TREPONEMAL SCR |
| 2 days |
| CARBAMAZEPINE |
| 3 days |
| OPIATES CONFIRMATION |
| 3 days |
| CCP ANTIBODIES IGG/IGM |
| 3 days |
| OSMOLALITY |
| 2 days |
| CELIAC DISEASE HLA |
| 7 days |
| OSMOLALITY, URINE |
| 2 days |
| CERULOPLASMIN |
| 3 days |
| OXYCODONE CONFIRMATION |
| 3 days |
| CHROMOGRANIN A |
| 5 days |
| PHENYTOIN |
| 4 days |
| CMV ABS IGG/IGM |
| 4 days |
| PHOSPHORUS, URINE |
| 2 days |
| CMV PCR QUAL |
| 4 days |
| PROGESTERONE |
| 3 days |
| COPPER |
| 4 days |
| PROSTATE CANCER G3 |
| 6 days |
| DRUG SCREEN BLOOD |
| 3 days |
| PROTEIN C-FUNCTIONAL |
| 4 days |
| DS- DNA ANTIBODY |
| 3 days |
| PROTEIN S-FUNCTIONAL |
| 4 days |
| EBV ACUTE INFECTION |
| 3 days |
| QUANTIFERON |
| 2 days |
| ENDOMYSIAL ANTIBODY |
| 4 days |
| RETICULIN IGA AB |
| 4 days |
| ERYTHROPOIETIN (EPO) |
| 4 days |
| RPR |
| 2 days |
| ESTRADIOL |
| 4 days |
| T3 REVERSE |
| 3 days |
| ESTROGENS FRACTIONAT |
| 4 days |
| T3 UPTAKE, SERUM |
| 3 days |
| ESTRONE, SERUM |
| 4 days |
| THYROGLOBULIN ABS |
| 4 days |
| ETHYL GLUCURONIDE |
| 3 days |
| THYROID ANTIBODIES |
| 4 days |
| ETHYL GLUCURONIDE URINE |
| 3 days |
| THYROID PEROXIDASE |
| 3 days |
| FACTOR V LEIDEN |
| 4 days |
| THYROXINE (T4) |
| 3 days |
| FECAL FAT, QUAL |
| 3 days |
| TRAMADOL SCREEN, UR |
| 3 days |
| FIBRINOGEN ACTIVITY |
| 2 days |
| TREPONEMA PALLIDUM ABS |
| 3 days |
| GIARDIA LAMBLIA AG, |
| 2 days |
| TRIIODOTHYRONINE |
| 3 days |
| GLIADIN IGG/IGA AB P |
| 4 days |
| TRIIODOTHYRONINE,FREE |
| 3 days |
| H. PYLORI STOOL AG, |
| 4 days |
| T-TRANSGLUTAMINASE |
| 3 days |
| H. PYLORI, IGG ABS |
| 4 days |
| VITAMIN B1 |
| 3 days |
| HBV REAL-TIME PCR |
| 5 days |
| VITAMIN B6, PLASMA |
| 4 days |
| HCG,BETA SUBUNIT, QN |
| 2 days |
| VITAMIN D 1,25 |
| 4 days |
| HCV FIBROSURE |
| 5 days |
| VITAMIN E, SERUM |
| 3 days |
| HEAVY METALS PROFILE |
| 4 days |
| VZ VIRUS DNA, QN |
| 3 days |
| HELPER T-LYMPH-CD4 |
| 3 days |
| Microbiology Test Name |
| TAT in days |
| CPT Code |
| BLOOD CULTURE, ROUTINE |
| 5 day |
| 87040 |
| AEROBIC BACTERIAL CU |
| 2 day |
| 87070 |
| BODY FLUID CULTURE |
| 5 day |
| 87070 |
| GENITAL CULTURE |
| 2 day |
| 87070 |
| SPUTUM CULTURE |
| 2 day |
| 87070 |
| ANAEROBE ID/SUSCEPT |
| 5 day |
| 87076 |
| AEROBE ID + SUSCEPT |
| 2 day |
| 87077 |
| BETA STREP GP A CULTURE |
| 1 day |
| 87081 |
| STREP B CULTURE |
| 2 day |
| 87081 |
| URINE CULTURE, ROUTINE |
| 2 day |
| 87086 |
| ORGANISM IDENTIFICAT |
| Case by case basis, 7-28 day |
| 87107 |
| SUSCEPTIBILITY |
| 4 day |
| 87184 |
| MIC ORGANISM #1 |
| Case by case basis, 2-28 day |
| 87186 |
| MIC ORGANISM #2 |
| Case by case basis, 2-28 day |
| 87186 |
| MIC ORGANISM #3 |
| Case by case basis, 2-28 day |
| 87186 |
| MIN INHIBITORY CONC |
| 4 day |
| 87186 |
| SENSITIVITY ORGANISM |
| 4 day |
| 87186 |
| VIRAL CULTURE |
| Case by case basis, 4-24 day |
| 87252 |
| VIRAL CULTURE,RAPID |
| 4 day |
| 87254 |
| HSV CULTURE & TYPIING |
| 5 day |
| 87255 |
| E COLI TOXIN W/RF O157 |
| 2 day |
| 87427 |
| INFLUENZA A&B PCR |
| 2 day |
| 87502 |
| MTB NAA WITHOUT AFB |
| 4 day |
| 87556 |
| CELL CT FLUID |
| 1 day |
| 89051 |
CHEMISTRY FLUID PANEL
3 day 82945 ,84157 ,82042 ,83615
| CELL CT SYNOVIAL |
| 1 day |
| 83872 ,89051 ,89060 |
| STOOL CULTURE |
| 6 day |
| 87045 ,87046 ,87427 |
| ANAEROBIC & AEROBIC |
| 6 day |
| 87070 ,87075 |
| ANAEROBIC CULTURE |
| 5 day |
| 87075, 87205 |
| FUNGUS CULTURE |
| Case by case basis, 28-42 day |
| 87101 ,87206 |
| OVA + PARASITE EXAM |
| 7 day |
| 87177 ,87209 |
| ACID FAST SMEAR & CULTURE |
| 51 day |
| 87206 ,87116 |
| CHLAMYDIA/GC AMPLIFICATION |
| 3 day |
| 87491 ,87591 |
| CT/GC NAA, RECTAL |
| 3 day |
| 87491 ,87591 |
BACKGROUND INVESTIGATIONS AND SPECIAL AGREEMENT CHECKS
All Reference Laboratory employees are subject to the same level of investigation as VA employees who have access to VA sensitive information. The level of background investigation commensurate with the level of access needed to perform the work is: Low Risk. This requirement is applicable to all subcontractor personnel requiring the same access.
The Reference Laboratory shall bear the expense of obtaining background investigations. If the investigation is conducted by the Office of Personnel Management (OPM) through the VA, the Reference Laboratory shall reimburse the VA within 30 days.
VA INFORMATION SECURITY LANGUAGE
General
Contractors, contractor personnel, subcontractors, and subcontractor personnel shall be subject to the same Federal laws, regulations, standards and VA Directives and Handbooks as VA and VA personnel regarding information and information system security.
Access to VA Information and VA Information Systems
a. A contractor/subcontractor shall request logical (technical) or physical access to VA information and VA information systems for their employees, subcontractors, and affiliates only to the extent necessary to perform the services specified in the contract, agreement or task order.
b. All contractors, subcontractors, and third party servicers and associates working with VA information are subject to the same investigative requirements as those of VA appointees or employees who have access to the same types of information. The level and process of background security investigations for contractors must be in accordance with VA Directive and Handbook 0710, Personnel Suitability and Security Program. The Office for Operations, Security, and Preparedness is responsible for these policies and procedures.
c. Contract personnel who require access to national security programs must have a valid security clearance. National Industrial Security Program (NISP) was established by executive Order 12829 to ensure that cleared US defense industry contract personnel safeguard the classified information in their possession while performing work on contracts, programs, bids, or research and development efforts. The Department of Veteran Affairs does not have a Memorandum of Agreement with Defense Security Services (DSS). Verification of a Security Clearance must be processed through the Special Security Officer located in the Planning and National Security Service within the Office of Operations, Security, and Preparedness.
d. Custom software development and outsourced operations must be located in the US to the maximum extent practical. If such services are proposed to be performed abroad and are not disallowed by other VA policy or mandates, the contractor/subcontractor must state where all non-US services are provided and detail a security plan, deemed to be acceptable to VA, specifically to address mitigation of the resulting problems of communication, control, data protection, and so forth. Location within the US may be an evaluation factor.
e. The contractor or subcontractor must notify the Contracting Officer immediately when an employee working on a VA system or with access to VA information is reassigned or leaves the contractor or subcontractor's employ. The Contracting Officer must also be notified immediately by the contractor or subcontractor prior to an unfriendly termination.
Custody of VA Information
a. Information made available to the contractor or subcontractor by VA for the performance or administration of the contract shall be used only for the purposes and shall not be used in any other way without the written agreement of the VA. This clause expressly limits the contractor/subcontractor's rights to use data as described in Rights of Data – General, FAR 52.227-14(d) (1).
b. VA information should not be co-mingled, if possible, with any other data on the contractor/subcontractor's information systems or media storage systems in order to ensure VA requirements related to data protection and media sanitization can be met. If co-mingling must be allowed to meet the requirements of the business need, the contractor must ensure that VA's information is returned to the VA or destroyed in accordance with VA's sanitization requirements. VA reserves the right to conduct onsite inspections of contractor and subcontractor IT resources to ensure data security controls, separation of data and job duties, and destruction/media sanitization procedures are in compliance with VA directive requirements.
c. Prior to termination or completion of this contract, contractor/subcontractor must not destroy information received from VA, or gathered / created by the contractor in the course of performing the contract without prior written approval by the VA. Any data destruction done on behalf of VA by a Contractor/subcontractor must be done in accordance with VA Directive 6300, Records and Information Management and its Handbook 6300.1, Electronic Media Sanitization. Self0-certification by the contractor that the data destruction requirements above have been met must be sent to the VA Contracting Officer within 30 days of termination of the contract.
d. The contractor/subcontractor must receive, gather, store, back up, maintain, use, disclose and dispose of VA information only in compliance with the terms of the contract and applicable Federal and VA information confidentiality and security laws, regulations and policies. If Federal or VA information confidentiality and security laws, regulations and policies become applicable to the VA information or information systems after execution of the contract, or if NIST issues or updates applicable to FIPS or Special Publications (SP) after execution of this contract, the parties agree to negotiate in good faith to implement the information confidentiality and security laws, regulations and policies in this contract.
e. The contractor/subcontractor shall not make copies of VA information except as authorized and necessary to perform the terms of the agreement or to preserve electronic information stored on contractor/subcontractor electronic storage media for restoration in case any electronic equipment or date used by the contractor/subcontractor needs to be restored in an operating state. If copies are made for restoration purposes, after the restoration is complete, the copies must be appropriately destroyed.
f. If VA determines that the contractor has violated any of the information confidentiality, privacy, and security provisions of the contract, it shall be sufficient grounds for VA to withhold payment to the contractor or third party or terminate the contract for default or terminate for cause under FAR Part 12.
g. If a VHA contract is terminated for cause, the associated BAA must also be terminated an appropriate actions taken in accordance with VHA Handbook 1600.01, Business Associate Agreements. Absent an agreement to use or disclose protected health information, there is no business relationship.
h. The contractor/subcontractor must store, transport, or transmit VA sensitive information in an encrypted form, using VA-approved encryption tools that are, at a minimum, FIPS 140-2 validated.
i. The contractor/subcontractor's firewall and Web services security controls, if applicable, shall meet or exceed VA's minimum requirements. VA Configuration Guidelines are available upon request.
j. Except for uses and disclosures of VA information authorized by this contract for performance of the contract, the contractor/subcontractor may use and disclose VA information only in two other situations:
(i) in response to a qualifying order of a court of competent jurisdiction, or (ii) with VA's prior written approval. The contractor/subcontractor must refer all requests for, demands for production of, or inquiries about, VA information and information systems to the VA contracting officer for response.
k. Notwithstanding the provision above, the contractor/subcontractor shall not release VA records protected by Title 38 U.S.C. 5705, confidentiality of medical quality assurance records and/or Title 38 U.S.C. 7332, confidentiality of certain health records pertaining to drug addiction, sickle cell anemia, alcoholism, or alcohol abuse, or infection with human immunodeficiency virus. If the contractor/subcontractor is in receipt of a court order or other requests for the above mentioned information, the contractor/subcontractor shall immediately refer such court orders or other requests to the VA Contracting Officer for response.
l. For service that involves the storage, generating, transmitting, or exchanging of VA sensitive information but does not require C&A or an MOU-ISA for system interconnection, the contractor/subcontractor must complete a Contractor Security Control Assessment (CSCA) on a yearly basis and provide it to the COTR.
Security Incident Investigation
a. The term "security incident" means an event that has, or could have, resulted in unauthorized access to, loss or damage to VA assets, or sensitive information, or an action that breaches VA security procedures. The contractor/subcontractor shall immediately notify the Contracting Officer and the COTR and simultaneously, the designated ISO and Privacy Officer for the contract of any known or suspected security/privacy incidents, or any unauthorized disclosure of sensitive information, including that contained in system(s) to which the contractor/subcontractor has access.
b. To the extent known by the contractor/subcontractor, the notice to VA shall identify the information involved, the circumstances surrounding the incident (including to whom, how, when, and where the VA information or assets were placed at risk or compromised), and any other information that the contractor/subcontractor considers relevant.
c. With respect to unsecured protected health information, the business associate is deemed to have discovered a date breach when the business associate knew or should have known of a breach of such information. Upon discovery, the business associate must notify the covered entity of the breach. Notifications need to be made in accordance with the executed business associate agreement.
d. In instances of theft, break-in, or other criminal activity, the contractor/subcontractor must concurrently report the incident to the appropriate law enforcement entity (or entities) of jurisdiction, including the VA OIG and Security and Law Enforcement. The Contractor, its employees, and its subcontractors and their employees shall cooperate with VA and any law enforcement authority responsible for the investigation and prosecution of any possible criminal law violation(s) associated with any incident. The contractor/subcontractor shall cooperate with VA in any civil litigation to recover VA information, obtain monetary or other compensation from a third party for damages arising from any incident, or obtain injunctive relief against any third party arising from, or related to, the incident.
Liquidated Damages for Data Breach
a. Consistent with the requirements of 38U.S.C. 5725, a contract may require access to sensitive personal information. If so, the contractor is liable to VA for liquidated damages in the event of a data breach or privacy incident involving any SPI the contractor/subcontractor processes or maintains under the contract.
b. The contractor/subcontractor shall provide notice to VA of a "security incident" as set forth in the Security Incident Investigation section above. Upon such notification, VA must secure from a non- Department entity of the VA Office of Inspector General an independent risk analysis of the data breach to determine the level of risk associated with the date breach for the potential misuse of any sensitive personal information involved in the data breach. The term "data breach" means the loss, theft, or other unauthorized access, or any access other than that incidental to the scope of employment, to data containing sensitive personal information, in electronic or printed form, that results in the potential compromise of the confidentiality or integrity of the data. Contractor shall fully cooperate with the entity performing the risk analysis. Failure to cooperate may be deemed a material breach and grounds for contract termination.
c. Each risk analysis shall address all relevant information concerning the data breach, including the following:
1. Nature of event (loss, theft, unauthorized access);
2. Description of the event, including:
a. Date of occurrence
b. Date elements involved, including any PII, such as full name, social security number, date of birth, home address, account number, disability code:
3. Number of individuals affected or potentially affected;
4. Names of individuals or groups affected or potentially affected;
5. Ease of logical date access to the lost, stolen, or improperly accessed data in light of the degree of protection for the data, e.g. unencrypted, plain text;
6. Amount of time the data has been out of VA control;
7. The likelihood that the sensitive personal information will or has been compromised (made accessible to and usable by unauthorized persons);
8. Known misuses of date containing sensitive personal information, if any;
9. Assessment of the potential harm to the affected individuals;
10. Data breach analysis as outlined in 6500.2 Handbook, Management of Security and Privacy Incidents, as appropriate; and
11. Whether credit protection services may assist record subjects in avoiding or mitigating the results of identity theft based on the sensitive personal information that may have been compromised.
d. Based on the determinations of the independent risk analysis, the contractor shall be responsible for paying to the VA liquidated damages of $37.50 per affected individual to cover the cost of providing credit protection services to affected individuals consisting of the following:
1. Notification;
2. One year of credit report monitoring services consisting of automatic daily monitoring of at least 3 relevant credit bureau reports;
3. Data breach analysis;
4. Fraud resolution services, including writing dispute letters, initiating fraud alerts and credit freezes, to assist affected individuals to bring matters to resolution;
5. One year of identity theft insurance with $20,000 coverage at $0 deductible; and
6. Necessary legal expenses the subjects may incur to repair falsified or damaged credit records, histories, or financial affairs.
Security Controls Compliance Testing
On a periodic basis, VA, including the Office of Inspector General, reserves the right to evaluate any or all of the security controls and privacy practices implemented by the contractor under the clauses contained within the contract. Within 10 working day notice, at the request of the government, the contractor must fully cooperate and assist in a government sponsored security controls assessment at each location wherein VA information is processed or stored, or information systems are developed operated, maintained, or used on behalf of VA, including those initiated by the Office of Inspector General. The government may conduct a security control assessment on shorter notice (to include unannounced assessments) as determined by VA in the event of a security incident or at any other time.
Training
a. All contractor employees and subcontractor employees requiring access to VA information and VA information systems shall complete the following before being granted access to VA information and its systems:
1. Sign and acknowledge (either manually or electronically) understanding of and responsibilities for compliance with the Contractor Rules of Behavior, Appendix E relating to access to VA information and information systems;
2. Successfully complete the VA Cyber Security Awareness and Rules of Behavior training and annually compete the required security training;
3. Successfully complete the appropriate VA privacy training and annually complete required privacy training; and
4. Successfully complete any additional cyber security or privacy training, as required for VA personnel with equivalent information system access.
b. The contractor shall provide to the Contracting Officer and/or the COTR a copy of training certificates and certification of signing the Contractor Rules of Behavior for each applicable employee within 1 week of the initiation of the contract and annually thereafter, as required.
c. Failure to complete the mandatory annual training and sign the Rules of Behavior annually, within the timeframe required, is grounds for suspension or termination of all physical or electronic access privileges and removal from work on the contract until such time as the training and documents are complete.
Table B Reference Test Menu Required as well as average annual Boise VA Laboratory Send-Out Volume
TEST DESCRIPTION
CPT CODES
TOTAL
1 year volume
| Drug Monitoring |
| 80307 |
| 1075 |
| QUANTIFERON(R)-TB GOLD, 1 |
| 86480 |
| 718 |
| RPR (MONITOR) WITH REF |
| 86592 |
| 693 |
| PEP W/TOTAL, RFX IFE |
| 84155, 84165 |
| 609 |
| C.TRACHO/N.GONO RNA, TMA |
| 87491, 87591 |
| 530 |
| ANA SCREEN, IFA, RFLX |
| 86038 |
| 432 |
| MMR(IGG)PNL,IMMUNE STATUS |
| 86735, 86762, 86765 |
| 421 |
| DRUG TEST, GENERAL TOX |
| CKWEB |
| 329 |
| METHYLMALONIC ACID |
| 83921 |
| 271 |
| IMMUNOFIXATION, SERUM |
| 86334 |
| 267 |
| Opiate Confirmation, Urine |
| 80361 |
| 229 |
| TACROLIMUS HIGH SENSITIV |
| 80197 |
| 214 |
| KAPPA/LAMBDA LHT CHN FREE |
| 83520 (2) |
| 212 |
| CCP IGG ANTIBODIES |
| 86200 |
| 163 |
| SYPHILIS AB CASCADING |
| 86780 |
| 158 |
| TISSUE TRANSGLUT IGA |
| 83516 |
| 153 |
| LYMPHOCYTE SUBSET PNL2 |
| 86355, 86359, 86360 |
| 148 |
Amphetamine Confirmation Urine
80324
| REFLEX ANA, TIT AND PA |
| 86039 |
| 136 |
| VIT B1 (THIAMINE), BLD |
| 84425 |
| 135 |
| HIV-1 QUANTITATION RT PCR |
| 87536 |
| 132 |
| VITAMIN D, 1,25-OH |
| 82652 |
| 121 |
Benzodiazepine, Confirmation Urine
80346
| TRAMADOL, SCREEN W/ CONF. |
| 80307 |
| 102 |
| ALPHA-1-ANTITRYPSIN QUAN |
| 82103 |
| 98 |
| CULT, FUNGUS, MISC SOURCE |
| 87102 |
| 97 |
| IMMUNOGLOBULIN E |
| 82785 |
| 79 |
| H PYLORI AG STOOL |
| 87338 |
| 77 |
| REFLX TRAMADOL METAB, QN |
| 80373 |
| 77 |
| ALDOSTERONE/PL RENIN A |
| 82088, 84244 |
| 76 |
| STONE ANALYSIS WITH IMAGE |
| 82365 |
| 76 |
| CHROM, HEMATOLOGIC |
| 88237, 88264 |
| 72 |
| Oxycodone, Confirmation Urine |
| 80365 |
| 71 |
| CARDIOLIPIN AB A,G,M |
| 86147 (3) |
| 64 |
| LEU & LYM 22 MARKERS |
| 88184, 88185 (21), 88189 |
| 62 |
| PROTEIN ELECTRO EVAL |
| 82570, 84156, 84166 |
| 62 |
| VZV IGG & IGM ABS |
| 86787 (2) |
| 60 |
| THYROID CANCER MONITOR |
| 86800 |
| 60 |
| PROT.ELEC,RANDURN W |
| 82570, 84156, 84166 |
| 59 |
| BCR-ABL1 GENE REARRANG |
| 81206 |
| 58 |
| METHYLMALONIC ACID, GC |
| 82570, 83921 |
| 57 |
| DHEA, UNCONJUGATED |
| 82626 |
| 56 |
| REFLEX P210 BCR-ABL1 |
| 81206 |
| 56 |
| ACTIN (SMOOTH MUSCLE) |
| 83516 |
| 55 |
| (AAT) QN AND PHENOTYPE |
| 82103, 82104 |
| 55 |
| HBV B DNA QUANT REAL-TIME |
| 87517 |
| 54 |
| BETA-2-GLY IGG IGM IGA |
| 86146 (3) |
| 54 |
| ANCA SCREEN W/REFLX T |
| 86021 |
| 54 |
| THYROID PEROX AND THY AB |
| 86376, 86800 |
| 47 |
| CYCLOSPORINE A, TROUGH |
| 80158 |
| 46 |
| HEAVY METALS PANEL (VENO) |
| 82175, 83655, 83825 |
| 45 |
| CALPROTECTIN, STOOL |
| 83993 |
| 45 |
| LUPUS ANTICOAGULANT EVAL |
| 85613, 85730 |
| 43 |
| HSV 1 & 2 IGG ABS |
| 86695, 86696 |
| 41 |
| HEREDITARY HEMOCHROM |
| 81256 |
| 41 |
| SJOGREN'S ABS (SS-A,SS |
| 86235 (2) |
| 40 |
| YEAST IDENTIFICATION 1 |
| 87106 |
| 40 |
| IMMUNOFIXATION, SERUM |
| 86334 |
| 39 |
| 5-HIAA 24HR URN W/CREA |
| 82570, 83497 |
| 37 |
| FACTOR V (LEIDEN) MUT |
| 81241 |
| 36 |
| JAK2 V617F CASCADINGRF |
| 81219, 81270, 81279, 81339, 81479 |
| 36 |
| DNA (DS) ANTIBODY |
| 86225 |
| 34 |
| MITOCHONDRIAL M2 AB IGG |
| 83520 |
| 34 |
| ENDOMYSIAL AB SCRN RFLX |
| 86255 |
| 34 |
| CMV DNA QN RT PCR |
| 87497 |
| 32 |
URORISK(R) DIAGNOSTIC P
82340, 82507, 82570, 83735, 83945, 83986, 84105, 84133, 84300, 84392, 84560
| HSV 1/2 AB IFA W/RFX TITR |
| 86695, 86696 |
| 29 |
| PROTH (FACT II) 20210G |
| 81240 |
| 28 |
| LYME AB W/RFX IGG/IGM |
| 86618 |
| 27 |
| CHLAM TRAC/NEIS.THROAT |
| 87491, 87591 |
| 27 |
| FISH,MDS/MYELOID PNL |
| 88271 (6), 88275 (3) |
| 26 |
| REFLEX P190 BCR-ABL1 |
| 81207 |
| 26 |
| CMV IGG/M ABS |
| 86644, 86645 |
| 25 |
| IGG TOTAL W/SUBCLASS 123 |
| 82784, 82787 (4) |
| 24 |
| HERPES SIMPLEX VIRUS, |
| 87529 (2) |
| 24 |
| GLUTAMIC ACID DECARBOX |
| 86341 |
| 23 |
| NICOTINE&COTININE |
| 80323 |
| 23 |
WILD CODE AMBIENT
| HEPATITIS BE PANEL |
| 86707, 87350 |
| 22 |
| BK VIRUS DNA, QUANTITA |
| 87799 |
| 22 |
| CHLAM TRAC/NEIS.RECTAL |
| 87491, 87591 |
| 22 |
| METANEPH, FREE, PLASMA |
| 83835 |
| 22 |
| TRAB (TSH RECEPTOR AB) |
| 83520 |
| 21 |
| PROTEIN C & S ACTIVITY |
| 85303, 85306 |
| 21 |
WILD CODE FROZEN
| SM AND SM/RNP ANTI |
| 86235 (2) |
| 20 |
| CORTISOL FREE, 24HR UR |
| 82530 |
| 20 |
| MYCOPL PNEUM DNA, QL |
| 87581 |
| 18 |
| VITAMIN E (TOCOPHEROL) |
| 84446 |
| 17 |
| FECAL FAT, QUALITATIVE |
| 82705 |
| 17 |
| LEGIONELLA DNA,QLRTPCR |
| 87541, 87798 |
| 17 |
| BETA-HYDROXYBUTYRATE |
| 82010 |
| 17 |
| FREE KAPPA/LAMBDA W/KL |
| 83883 (2) |
| 17 |
| VITAMIN A (RETINOL) |
| 84590 |
| 16 |
| **STONE ANALYSIS |
| 82365 |
| 16 |
| CYTOMEGALOVIRUS DNA QL |
| 87496 |
| 16 |
| INTERLEUKIN-6 (IL-6) |
| 83520 |
| 16 |
| MYASTHENIA GRAVIS PNL2 |
| 83519 (3) |
| 16 |
| REFLEX DRVVT CONFIRM |
| 85597 |
| 16 |
| REFLEX RPR TITER |
| 86593 |
| 16 |
| CHLAMYDOPHILA PNEU DNA |
| 87486 |
| 16 |
| ALK PHOSPHATASE ISOENZ |
| 84075, 84080 |
| 15 |
| GLIADIN AB (IGG, IGA) |
| 83516 (2) |
| 15 |
| CRYOGLOBULIN SCREEN WITHL |
| 82595 |
| 15 |
| REFLEX MUSK AB TEST |
| 83519 |
| 15 |
| EBV AB PANEL |
| 86664, 86665 (2) |
| 14 |
| MYELOPEROXIDASE AB |
| 86021 |
| 14 |
| SIROLIMUS LC/MS/MS |
| 80195 |
| 14 |
| BILL ONLY PNEUMOCYSTI |
| 87015, 87281 |
| 14 |
| **PM ALCOHOL METAB |
| 80321 |
| 14 |
| ANTITHROMBIN III ANT |
| 85301 |
| 13 |
| RESPIRATORY VIRUS SCRE |
| 87300 |
| 13 |
| METANEP, FRAC, 24HR UR |
| 83835 |
| 13 |
| MULTIPLE SCLEROSIS PAN |
| 82040, 82042, 82784 (2), 83916 |
| 13 |
| T3 REVERSE, LC/MS/MS |
| 84482 |
| 13 |
| CYSTATIN C WITH EGFR |
| 82610 |
| 13 |
| FISH-B-CELL CLL PNL |
| 88271 (6), 88275 (3) |
| 12 |
| FISH, MYELOMA W/REFLEXES |
| 88271 (11), 88275 (5) |
| 12 |
| MONOCLONAL GAMMOPATH U |
| 86335 |
| 12 |
| HETEROPHILE, MONO SCRN |
| 86308 |
| 12 |
| ANGIOTENSIN CONVERTING EN |
| 82164 |
| 12 |
| BETA-2-MICROGLOBULIN, SER |
| 82232 |
| 12 |
| FUNGITELL(R)(1-3)BD-GL |
| 87449 |
| 12 |
| PROTEINASE-3 ANTIBODY |
| 86021 |
| 12 |
| EPSTEIN-BARR VIRUS |
| 87798 |
| 12 |
| KAPPA/LAMBDA CHAINS UR |
| 83883 (2) |
| 12 |
| CATECHOLAMINES, FRACTI |
| 82384, 82570 |
| 12 |
| RFLX HEXAGONAL PHASE CONF |
| 85598 |
| 12 |
| BILL ONLY LEUK/LYMP EV |
| 88184, 88185 (21), 88189 |
| 12 |
| RNA POLYMERASE III |
| 83516 |
| 12 |
| LEU & LYM 25 MARKERS |
| 88184, 88185 (24), 88189 |
| 11 |
| ANTITHROMBIN III ACT |
| 85300 |
| 11 |
| INFLIXIMAB LEV/AB, IBD |
| 80230, 83520 |
| 11 |
| VIT B2 (RIBOFLAVIN), PLA |
| 84252 |
| 11 |
| Methadone, Confirmation Urine |
| 80358 |
| 11 |
| COCCIDIODIDES AB |
| 86635 (2) |
| 11 |
| LEUK&LYMP EVAL, 26 MARKR |
| 88184, 88185 (25), 88189 |
| 10 |
| HERPES SIMPLEX W/ REFL |
| 87255 |
| 10 |
| P16,IHC W/O INTERP |
| 88342 |
| 9 |
| PARVOVIRUS B19 ANTIBOD |
| 86747 (2) |
| 9 |
| MOLD IDENTIFICATION 1 |
| 87107 |
| 9 |
| MYOSITIS SPEC 11 ABS PAN |
| 84182 (6), 86235 (5) |
| 9 |
| FISH, HIGH-GRADE LYMPHOMA |
| 88271 (6), 88275 (3) |
| 8 |
| ANTI-STREPTOLYSIN O AB |
| 86060 |
| 8 |
| HEP-INDUCED PLT AB |
| 86022 |
| 8 |
| PROTEIN C ANTIGEN |
| 85302 |
| 8 |
| PROTEIN S AG, TOTAL |
| 85305 |
| 8 |
| PANCREATIC ELASTASE 1 |
| 83520 |
| 8 |
| DIPHTHERIA & TETANUS |
| 86648, 86774 |
| 8 |
| HEMOGLOBINOPATHY EVALU |
| 83020, 85014, 85018, 85041 |
| 8 |
| MYELIN ASSOC GYLCOPROT |
| 83520 |
| 8 |
| Cannabinoids SCREEN W/R |
| 80307 |
| 8 |
| RFX IMMUNOFIXATION,URN |
| 86335 |
| 8 |
| REFLEX RPR SCREEN |
| 86592 |
| 8 |
| EBV,ISH W/O INTERP |
| 88365TC |
| 7 |
| DHEA SULFATE, IMMUNOASSAY |
| 82627 |
| 7 |
| ESTROGEN, TOTAL, SERUM |
| 82672 |
| 7 |
| HEMOGLOBIN,FREE,PLASMA |
| 83051 |
| 7 |
| COMPLEMENT, TOTAL (CH50 |
| 86162 |
| 7 |
| THYROID PEROXIDASE AUTOAB |
| 86376 |
| 7 |
| STOOL ROUTINE CULTURE |
| CKWEB |
| 7 |
| S CEREVISIAE IGG & IGA |
| 86671 (2) |
| 7 |
| SUSCEP, YEAST, COMP PANEL |
| 87186 |
| 7 |
| STRONGYLOIDES ANTIBODY |
| 86682 |
| 7 |
| ESTROGENS, FRAC,LC/MS |
| 82671 |
| 7 |
| YEAST IDENTIFICATION 2 |
| 87106 |
| 7 |
STATEMENT OF WORK (SOW) for Reference Laboratory Services Boise VAMC Laboratory
| THROMBIN CLOTTING TIME |
| 85670 |
| 7 |
Buprenorphine, Confirmation Urine
80348
| OPIATE W/CONF PNL BV |
| 80307 |
| 7 |
| RFLX MARIJUANA MTBLT QUAN |
| 80349 |
| 7 |
| HYPERSENSITIVITY PNEUMON |
| CKWEB |
| 7 |
| CYCLIN D1,IHC W/O INTERP |
| 88342 |
| 6 |
| CD34,IHC W/O INTERP |
| 88342 |
| 6 |
| HER-2,IHC W/RFL FISH |
| 88360 |
| 6 |
| GLOMERULAR BASEMENT |
| 83520 |
| 6 |
| THYROGLOBULIN ANTIBODIES |
| 86800 |
| 6 |
| HISTOPLASMA AB, COMP F |
| 86698 (2) |
| 6 |
| CK CREATINE KIN ISOENZ |
| 82550, 82552 |
| 6 |
| FOOD ALLERGY PROFILE |
| 86003 (15) |
| 6 |
| STREP PNEU IGG AB 23 |
| 86317 (23) |
| 6 |
| PORPHYRINS, TOTAL PLA |
| 82542 |
| 6 |
| KAPPA/LAMBDA,ISHW/O INTRP |
| 88365TC (2) |
| 5 |
| T-CELL CLONALITY PNL |
| 81340, 81342, 84999 |
| 5 |
| LUNG CA (NSCLC),ROS1,FISH |
| 88271 (2), 88274 |
| 5 |
| COLD HEMAGGLUTININS |
| 86157 |
| 5 |
| OVA & PARASIT SMEAR |
| 87177, 87209 |
| 5 |
| SUSCEPTIBILITY, AEROBI |
| 87186 |
| 5 |
| INSULIN AUTOANTIBODY |
| 86337 |
| 5 |
| ISLET CELL AB SCRN W/R |
| 86341 |
| 5 |
| FOOD SPEC. IGG ALL PNL 2 |
| 86001 (13) |
| 5 |
| REFLEX DRVVT 1:1 MIX |
| 85613 |
| 5 |
| Barbiturates, Confirmation Urine |
| 80345 |
| 5 |
| PAX-5, IHC W/O INTERP |
| 88341 |
| 4 |
| MYD88, MUTATION ANALYSIS |
| 81305 |
| 4 |
| JAK2 V617F CASCADING REFL |
| 81270 |
| 4 |
| PD-L1, IHC W/ INTERP |
| 88360 |
| 4 |
| HER-2, FISH, PARAFFIN BL |
| 88377 |
| 4 |
SPECIAL TEST-PHENOPATH
| C1 ESTERASE INH, FUNCT |
| 86161 |
| 4 |
| LYSOZYME (MURAMIDASE) |
| 85549 |
| 4 |
| T4 (THYROXINE), TOTAL |
| 84436 |
| 4 |
| HEPATITIS D AB, TOTAL |
| 86692 |
| 4 |
| APOLIPOPROT EVALUATION |
| 82172 (2) |
| 4 |
| HEAVY METALS PANEL, |
| 82175, 82570, 83655, 83825 |
| 4 |
| MAGNESIUM URINE 24H |
| 83735 |
| 4 |
| HSV VIRUS/VAR ZOSTER |
| 87254 (2) |
| 4 |
| NOROVIRUS RNA Q RT-PCR |
| 87798 |
| 4 |
| ELECTROLYTES, FECES |
| 82438, 84302, 84311 |
| 4 |
| OXCARBAZEPINE METABOLITE |
| 80183 |
| 4 |
| HU AB SCREEN W/REFLEX |
| 86255 |
| 4 |
| GIARDIA/CRYPTOSP AG |
| CKWEB |
| 4 |
| REFLEX HSV TYPE 2 |
| 87140 |
| 4 |
| NICOTINE & COTININE UR |
| 80323 |
| 4 |
| TRICHOMONAS VAGI, MALES |
| 87661 |
| 4 |
| ASPERGILLUS AB PANEL,C |
| 86606 (4) |
| 4 |
| RFX ATYPICAL P-ANCA TI |
| 86021 |
| 4 |
| THYROGLOBULIN,LC/MS/MS |
| 84432 |
| 4 |
| IMMUNE COMPLEX BY C1Q |
| 86332 |
| 4 |
| HISTONE ANTIBODIES |
| 83516 |
| 4 |
| CD20,IHC W/O INTERP |
| 88342 |
| 3 |
VWF AG,IHC W/O INTERP
| KI-67,IHC W/O INTERP |
| 88360 |
| 3 |
| CD138,IHC W/O INTERP |
| 88342 |
| 3 |
| FISH,AML,CBFB,MYH11,INV16 |
| 88271 (2), 88275 |
| 3 |
| FISH,MANTLE CELL LYMPHOMA |
| 88271 (2), 88275 |
| 3 |
| BRAF MUTATION ANALYSIS |
| 81210 |
| 3 |
| BCL-6, IHC W/O INTERP |
| 88341 |
| 3 |
| LUNG CA (NSCLC),ALK,FISH |
| 88271 (2), 88274 |
| 3 |
| PD-L1 LUNG HIVOLUMAB IHC |
| 88342 |
| 3 |
SPECIAL TEST-QUEST CHY
| PROTEIN C RESIST ACTIV |
| 85307 |
| 3 |
| STRIATED MUSCLE W/RFLX |
| 86255 |
| 3 |
| CATECHOLAMINES, FRACTI |
| 82384 |
| 3 |
| VMA, 24-HR URN (W/O C) |
| 84585 |
| 3 |
| TOXOPLASMA IGG & IGM |
| 86777, 86778 |
| 3 |
| OXALIC A 24HR U WO/C |
| 83945 |
| 3 |
| CHROMOSOM ANALYSIS BLD |
| CKWEB |
| 3 |
| GASTRIC PARIETAL CELL |
| 83516 |
| 3 |
| HLA-DR/DQ LOW R. TYPIN |
| 81375 |
| 3 |
| TSI (THYROID STIM IMM) |
| 84445 |
| 3 |
| BACTERIAL ID, AEROBIC |
| 87077 |
| 3 |
| HEAVY METALS 24H URINE |
| 82175, 83655, 83825 |
| 3 |
| PORPHYRINS,FRAC,QN,RAN |
| 84120 |
| 3 |
| CULTURE, FUNGUS, BLOOD |
| 87103 |
| 3 |
| ALPHA-1-ANTITRYPSIN |
| 82103 |
| 3 |
| PORPHOBLN RANDOM UR |
| 84110 |
| 3 |
| DELTA-AMINOLEVULINIC |
| 82135 |
| 3 |
| VZV DNA, QUANT R-T PCR |
| 87799 |
| 3 |
| ER/PR, PARAFFIN BLOCK |
| 88360 (2) |
| 2 |
| BCL-2,IHC W/O INTERP |
| 88341 |
| 2 |
| CD3,IHC W/O INTERP |
| 88342 |
| 2 |
| CD30,IHC W/O INTERP |
| 88342 |
| 2 |
| CD5,IHC W/O INTERP |
| 88342 |
| 2 |
| CD57,IHC W/O INTERP |
| 88342 |
| 2 |
| CD23,IHC W/O INTERP |
| 88342 |
| 2 |
| CD56,IHC W/O INTERP |
| 88342 |
| 2 |
| TTF-1,IHC W/O INTERP |
| 88342 |
| 2 |
| PAP,IHC W/O INTERP |
| 88342 |
| 2 |
| PSA,IHC W/O INTERP |
| 88341 |
| 2 |
| FISH,MALT REA18Q21 W/RFL |
| 88271 (2), 88275 |
| 2 |
| HEPPAR 1, IHC W/O INTERP |
| 88341 |
| 2 |
| MUM1,IHC W/O INTERP |
| 88342 |
| 2 |
| LEU & LYM 23 MARKERS |
| 88184, 88185 (22), 88189 |
| 2 |
| P53,IHC W/O INTERP |
| 88342 |
| 2 |
| ALK 1,IHC W/O INTERP |
| 88341 |
| 2 |
| LEUK&LYMP EVAL, 27 MARKR |
| 88184, 88185 (26), 88189 |
| 2 |
| LEUKOVANTAGE(TM) (AML) |
| 81450 |
| 2 |
| LEUKOVANTAGE(TM),(MDS) |
| 81450 |
| 2 |
| FISH,MPN (EOSINOPHILIA) |
| 88271 (7), 88275 (3) |
| 2 |
| LYNCHSYND TUMR,IHC INTERP |
| 88342, 88341 (x3) |
| 2 |
| FISH, MYELOMA, IGH PANEL |
| 88271 (8), 88275 (4) |
| 2 |
SPECIAL TEST-ARUP
| C1 ESTERASE INHIB,PROTEIN |
| 86160 |
| 2 |
| RUBELLA ANTIBODY (IGM) |
| 86762 |
| 2 |
| CITRIC ACID, 24H UA |
| 82507, 82570 |
| 2 |
| ADRENAL AB W/RFX TO TITER |
| 86255 |
| 2 |
| PORPHOBLN RANDOM URINE |
| 84110 |
| 2 |
| LYME DIS (IGG,IGM) |
| 86617 (2) |
| 2 |
| PROTEIN S ANTIG, FREE |
| 85306 |
| 2 |
| MYCOPHEN ACID LS/MS/MS |
| 80180 |
| 2 |
| CRYPTO AG/SCREEN/REF |
| 86403 |
| 2 |
| ASPERGILLUS ANTIG, SER |
| 87449 |
| 2 |
| HIV-1 INTEGRASE GENOTY |
| 87906 |
| 2 |
| ADA, PLEURAL FLUID |
| 84311 |
| 2 |
| SUC,ANTIMIC,A.BAC,MIC |
| 87186 |
| 2 |
| H INFLUENZAE B IGG ABS |
| 86684 |
| 2 |
| GANGLIOSIDE (IGG,IGM) |
| 83520 (2) |
| 2 |
| GASTROINTESTINAL PAT |
| 87506 |
| 2 |
| PORPHOBILINOGEN,RNDM |
| 84110 |
| 2 |
| CULT, FUNGUS,SKIN,HAIR,NA |
| 87101 |
| 2 |
| REFLEX HSV TYPE 1 |
| 87140 |
| 2 |
| MANNAN BINDING LECTIN |
| 86161 |
| 2 |
| ANTI SUSC PANEL, ANA |
| 87181 (6) |
| 2 |
| CARDIO IQ(R) APOE GENO |
| 81401 |
| 2 |
| HISTOPLASMA GALAC AG,U |
| 87385 |
| 2 |
| HIV-1 RNA, QN R-T W/RF |
| 87536 |
| 2 |
| PARANEOPLASTIC AB EVAL |
| 83519 (5), 86255 (10) |
| 2 |
| CARDIO IQ(R) LP-PLA2 |
| 83698 |
| 2 |
| RFX TREPONEMA PALLIDUM |
| 86780 |
| 2 |
| HEPATITIS E AB (IGM) |
| 86790 |
| 2 |
| CD117,IHC W/O INTERP |
| 88342 |
| 1 |
| CD15,IHC W/O INTERP |
| 88342 |
| 1 |
| S-100,MONO,IHC W/O INTERP |
| 88341 |
| 1 |
| CD79A,IHC W/O INTERP |
| 88342 |
| 1 |
| CD10,IHC W/O INTERP |
| 88342 |
| 1 |
| TDT, IHC W/O INTERP |
| 88342 |
| 1 |
| CD31,IHC W/O INTERP |
| 88342 |
| 1 |
| CD61,IHC W/O INTERP |
| 88342 |
| 1 |
| CD99,IHC W/O INTERP |
| 88342 |
| 1 |
| CYTOKER 7,IHC W/O INTERP |
| 88342 |
| 1 |
| CYTOKER 8/18,W/O INTERP |
| 88342 |
| 1 |
| CYTOKER 19,W/O INTERP |
| 88342 |
| 1 |
| GRANZYME-B,IHC W/O INTERP |
| 88342 |
| 1 |
| WT1,IHC W/O INTERP |
| 88342 |
| 1 |
| SYNAPTOPHYSIN,W/O INTERP |
| 88342 |
| 1 |
| CALRETININ,IHC W/O INTERP |
| 88342 |
| 1 |
| CHROMOGRANIN,IHC W/O INT |
| 88342 |
| 1 |
| MOC-31,IHC W/O INTERP |
| 88341 |
| 1 |
CMV,IHC W/O INTERP
| CEA POLY, IHC W/O INTERP |
| 88342 |
| 1 |
| HHV-8,IHC W/O INTERP |
| 88342 |
| 1 |
| NSE, IHC W/O INTERP |
| 88341 |
| 1 |
| CMV,IHC W/ INTERP |
| 88342 |
| 1 |
| FISH,CML/ALL,BCR/ABL TRAN |
| 88271 (2), 88275 |
| 1 |
| FISH,AML,AML1/ETO T(8,21) |
| 88271 (2), 88275 |
| 1 |
| FISH, AML M3, PML/RARA, T |
| 88271 (2), 88275 |
| 1 |
| FISH, FOLLICULAR LYMPHOMA |
| 88271 (2), 88275 |
| 1 |
| AAT, IHC W/O INTERP |
| 88341 |
| 1 |
| PAN-CYTOKERATIN W/O INT |
| 88342 |
| 1 |
| TIA-1, IHC W/O INTERP |
| 88342 |
| 1 |
| FLT3 ITD AND TKD MUTATION |
| 0023U |
| 1 |
MELANOMA,BRAF V600
MUTATN
81210
| FISH, MECOM, 3Q26.2 |
| 88271 (2), 88275 |
| 1 |
| B-CELL CLONALITY, PCR |
| 81261, 81264, 84999 |
| 1 |
| COX-2, IHC W/O INTERP |
| 88342 |
| 1 |
| LUNG CANCER MUTATION PNL |
| 81235, 81275, 81276, 88271 (2), 88274 |
| 1 |
| MYOCARDIAL AB W/RFLX |
| 86255 |
| 1 |
| COPPER, 24-HOUR URINE |
| 82525 |
| 1 |
| INTRINSIC FACTOR BLOCK |
| 86340 |
| 1 |
| TREPONEMA PALLIDUM AB |
| 86780 |
| 1 |
| VASOACTIVE INTEST PO |
| 84586 |
| 1 |
| OSMOLALITY, FECES |
| 84999 |
| 1 |
| COMPLEMENT COMP. C1Q |
| 86160 |
| 1 |
| RHEUMATOID FACTOR |
| 86431 |
| 1 |
| CYTOMEGALOVIRUS, CON |
| 87252, 87254 |
| 1 |
| HERPES SIMPLEX VIRUS |
| 87255 |
| 1 |
| VALPROIC, ACID FREE |
| 80165 |
| 1 |
| RECOMBX(R) AMPH AUTOAB |
| 83520 |
| 1 |
| BETA-2-MICROGLOBULN URINE |
| 82232 |
| 1 |
| MAGNESIUM, RAND UR |
| 82570, 83735 |
| 1 |
| LYMPHOCYTE SUBSET PANE |
| 86355, 86357, 86359, 86360 |
| 1 |
| URIC ACID URN 24HR W/O CR |
| 84560 |
| 1 |
| MODIFIED ACID FAST STA |
| 87206 |
| 1 |
| ADAMTS13 ACT W/RFX INH |
| 85397 |
| 1 |
| VIRAL RESP RAPID CULT |
| 87254 |
| 1 |
| ENTEROVIRUS RNA,QL R-T |
| 87498 |
| 1 |
| HLA TYPING FOR CELIAC |
| 81376 (2), 81382 (2) |
| 1 |
| PRPHYRNS,FRAC,QT,UR |
| 84110, 84120 |
| 1 |
| FISH, IGH/CCND, T(11;1 |
| CKWEB |
| 1 |
| MTHFR, DNA MUT. ANALYS |
| 81291 |
| 1 |
| DRUG ABUSE SCREEN, SER |
| 80307 |
| 1 |
| VZV DNA, QUAL R-T PCR |
| 87798 |
| 1 |
| MYCO PNEUMO IGG/M ABS |
| 86738 (2) |
| 1 |
| HERPESVIRUS 6 ABS (IGM) |
| 86790 |
| 1 |
| MEASLES ANTIBODY (IGM) |
| 86765 |
| 1 |
| ENTAMOEBA HISTOLYTICA |
| 86753 |
| 1 |
| HERPESVIRUS 6 AB (IGG) |
| 86790 |
| 1 |
| TOXOCARA AB (IGG), SER |
| 86682 |
| 1 |
| ADALIMUMAB LEV/AB, IBD |
| 80145, 83520 |
| 1 |
| MUMPS VIRUS AB (IGM) |
| 86735 |
| 1 |
| WEST NILE AB IGG/IGM |
| 86788, 86789 |
| 1 |
| FOOD/TREE ALG PNL W/RFLX |
| 86003 (17) |
| 1 |
| Q FEVER W/REFL TITERS |
| 86638 (4) |
| 1 |
| EPIDERMAL AB W/ REFLEX |
| 86255 (2) |
| 1 |
| BORDETELLA PERTU IGG |
| 86615 |
| 1 |
| ADENOSINE DEAMINASERBC |
| 84311 |
| 1 |
| VITAMIN B1 (THIAMINE) |
| 84425 |
| 1 |
| T-CELL RECEPTOR (TCR) |
| 81342, 84999 |
| 1 |
| SOLU TRANSFERRIN RECEPTOR |
| 84238 |
| 1 |
| ANAEROBIC MIC 1 |
| 87181 (6) |
| 1 |
| VON WILLEBRAND PANEL |
| 85240, 85245, 85246, 85730 |
| 1 |
| CLOSTRIDIUM DIFFICILE |
| 87324, 87449 |
| 1 |
| ANAEROBIC BACTERIA ID |
| 87076 |
| 1 |
| MOLD IDENTIFICATION 2 |
| 87107 |
| 1 |
| CALR MUTATION ANALYSIS |
| 81219 |
| 1 |
| BUPRENOPHONE&METABOLITES |
| 80348 |
| 1 |
| AQUAPORIN-4 ANTIBODY |
| 86255 |
| 1 |
| DRUG MONITORING ANTIDE |
| 80307 |
| 1 |
| ANTI-CN-1A (NT5C1A) IB |
| 83520 |
| 1 |
| POLIOVRUS AB NUTRALIZA |
| 86382 (2) |
| 1 |
| PLT AB SCREEN IND |
| 86022 (5) |
| 1 |
| PHOSPHORUS URINE 24H |
| 84105 |
| 1 |
| ADRENAL ANTIBODY TITER |
| 86256 |
| 1 |
ANTIDEPRESSANT(S)CONFIRM
| BILL ONLY LEUK/LYMP EV |
| 88184, 88185 (23), 88189 |
| 1 |
DEFINITIVE TEST 02
| RFL Q FEVER IGG PHASE II |
| 86638 |
| 1 |
| RFLX ENDO AB IGA TITER |
| 86256 |
| 1 |
| SCHISTOSOMA IGG SERUM |
| 86682 |
| 1 |
| TRICHINELLA IGG ABS |
| 86784 |
| 1 |
| FRANCISELLA TULARENSIS |
| 86000 |
| 1 |
| FECAL LIPIDS, TOTAL |
| 82710 |
| 1 |
| PROLACTIN, TOTAL/MONOM |
| 84146 (2) |
| 1 |
| HERPESVIRUS 6 DNA |
| 87532 |
| 1 |
| HTLV I/II DNA, QUAL |
| 87798 (2) |
| 1 |
| IODINE SERUM/PLASMA |
| 82542 |
| 1 |
| ASPERGILLUS AB,CF & |
| 86606 (4) |
| 1 |
| BK VIRUS DNA, QN, URN |
| 87799 |
| 1 |
| ANTIMICROBIAL SUSCEPT |
| 87181 |
| 1 |
| THROMBOPOIETIN (TPO) |
| 83520 |
| 1 |
14068